Cabozantinib is from which company?

Cabozantinib, sold under the brand names Cometriq and Cabometyx, is an anticancer drug used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc.

In November 2012, the U.S. Food and Drug Administration (FDA) approved cabozantinib capsule formulation, trade name Cometriq, for the treatment of medullary thyroid cancer. The capsule form was approved in the EU in 2014 for the same purpose. In April 2016, the FDA approved the marketing of a tablet formulation (Cabometyx) as a second-line treatment for kidney cancer and was approved in the EU in September of that year. The brands Cometriq and Cabometyx have different formulas and are not interchangeable.

As of now, cabozantinib has not been launched in China, so patients in need cannot purchase it directly from domestic hospitals. It is reported that the original research version and various generic versions of cabozantinib have been launched in overseas markets. The price of the original research version of tablets is about 35,000 yuan, while the price of capsules is about 46,000 yuan. Among them, the original research version of tablets produced in Türkiye is particularly outstanding in terms of cost performance. At the same time, the price of the generic version of cabozantinib available overseas is relatively affordable, ranging from about 800 to 7,600 yuan, providing patients with more choices. If you have more questions about cabozantinib, it is recommended to consult a regular overseas medical consulting company.